On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan to Set Up Dedicated Team to Expedite Review of Sakigake-Designated Cell/Gene Therapies
August 23, 2019
- Tecentriq Wins Japan Nod for SCLC as 1st Checkpoint Drug for This Use
August 23, 2019
- MHLW Orders Label Revision for Xeljanz to Add “Venous Thromboembolism” to ADR List
August 23, 2019
- MHLW Grants Orphan Status to Nippon Shinyaku’s DMD Med Viltolarsen
August 22, 2019
- No PMP for Tecentriq, but Prices Rise for All 5 Checkpoint Drugs in Tax Hike Re-Pricing
August 21, 2019
- MHLW Calls for Proper Price Negotiation after October Price Revision
August 21, 2019
- Annual Savings from Biosimilar Use Totaled Just 14.6 Billion Yen: MHLW
August 21, 2019
- Prices Go Up for 37% of Drugs, Down or Intact for 63% in Tax Hike Re-Pricing
August 20, 2019
- Kymriah, All Checkpoint Drugs but Tecentriq to Get Price Maintenance Premium in October Re-Pricing
August 20, 2019
- Rituxan’s Orphan Status Dropped for Rare Blood Disorder
August 16, 2019
- Japan’s 1st Forteo Biosimilar Could Get Listed in November
August 16, 2019
- First “Post-Nesp” Renal Anemia Med Could Land Japan Approval in September
August 16, 2019
- AbbVie’s Venetoclax Up for Review on Aug. 23; Tecentriq’s Breast Cancer Use, 2nd Biosimilars Also on Agenda
August 16, 2019
- Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time
August 16, 2019
- MHLW to Announce New Drug Prices on Aug. 19
August 9, 2019
- MHLW Gives Update on Heptavax, Seeks Cooperation in Stable Hep B Vaccine Supplies
August 8, 2019
- MHLW Compliance Chief Stresses Priorities on PMD Law Amendment, Steady Implementation of Detailing Guidelines
August 8, 2019
- MHLW Begins Discussions on Clinical Use of Human-Embryo Gene Editing
August 5, 2019
- MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
- Tecentriq’s SCLC Use Gets MHLW Panel Nod for September Approval
August 5, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…